Bio Path reported 0 in Sales Revenues for its fiscal quarter ending in March of 2025.





Sales Change Date
Alterity Therapeutics Limited AUD 11.38K 10.23K Dec/2022
Baxter International USD 2.97B 130M Dec/2025
Bio Path 0 0 Mar/2025
Cipla INR 75.18B 710M Dec/2025
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 1.89M 631K Sep/2025
CSL USD 8.33B 4.79B Dec/2025
Grifols EUR 2.34B 159.69M Mar/2026
Karyopharm Therapeutics USD 30.54M 8.24M Dec/2024